The Clinical Trial Regulation is currently being discussed. As patients, researchers, doctors, scientists and civil society representatives we would like to draw your attention not only to the dangers it encompasses but also to the opportunities it brings along.
The International Society of Drug Bulletins issued a statement today to the members of European Parlament to request:
The protection of human subjects must be upheld & citizens’ right to information must be strengthened
On 18 June 2012, the EU Commission published a draft concept paper for public consultation on the “Introduction of fees to be charged by the European Medicines Agency for pharmacovigilance”.
Joint Declaration: of HAI Europe, ISDB,AIM, BEUC, Medicines in Europe Forum
ISDB-Declaration-English dowload PDF (160 KB)
ISDB- Déclaration-French dowload PDF (160 KB)
ISDB-Deklaration-German dowload PDF (94 KB)
ISDB-Dichiarazione-Italian dowload PDF (170 KB)
ISDB-Declaration-Russian access to web page
ISDB-Declaration-Portuguese dowload PDF (171 KB)
ISDB-Declaración-Spanish dowload PDF (177 KB)
ISDB Information Booklet
Independence from drug companies is a key element of our policy
booklet october 2008 english (639 KB) - spanish (624 KB)
An opinion of the International Society of Drug Bulletins (ISDB)
Too much emphasis on medicines and not enough on health needs. All the more reason to switch EMEA from DG Trade to Health & Consumer Protection DG
ISDB Information Booklet
Independence from drug companies is a key element of our policy
booklet october 2008
Joint Declaration: of HAI Europe, ISDB,AIM, BEUC, Medicines in Europe Forum
ISDB - International Society of Drug bullettins
Contact details:
President: president@isdbweb.org
Webmaster: maria.font@ulss20.verona.it
© 2013